GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Float Percentage Of Total Shares Outstanding

Chromocell Therapeutics (Chromocell Therapeutics) Float Percentage Of Total Shares Outstanding : 75.68% (As of Jun. 22, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Chromocell Therapeutics's float shares is 4.37 Mil. Chromocell Therapeutics's total shares outstanding is 5.77 Mil. Chromocell Therapeutics's float percentage of total shares outstanding is 75.68%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Chromocell Therapeutics's Insider Ownership is 9.97%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Chromocell Therapeutics's Institutional Ownership is 0.00%.

Chromocell Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Chromocell Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=4.37/5.77
=75.68%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.

Chromocell Therapeutics (Chromocell Therapeutics) Headlines